VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2020 | The role of venetoclax in older patients with AML

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, outlines the role of venetoclax in older patients with acute myeloid leukemia (AML). Dr Wei highlights the phase III studies, VIALE-A (NCT02993523) and VIALE-C (NCT03069352), of venetoclax in combination with azacitidine or low-dose cytarabine. Additionally, he also discusses primary and adaptive resistance to venetoclax-based combinations associated with FLT3 and TP53 mutations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter